Overview
RARE market data
Price History
RARE price chart · 1M
- O
- 26.55
- H
- 26.57
- L
- 25.63
- C
- 26.45
- Vol
- 79,725.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $26.55
- Previous Close
- $26.46
- Day High
- $26.57
- Day Low
- $25.63
- 52 Week High
- $36.56
- 52 Week Low
- $18.29
- 7 Day Return
- +0.76%
- 30 Day Return
- -1.60%
- 90 Day Return
- +13.81%
- 1 Year Return
- +24.47%
- Daily Notional Volume
- $2.1M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$5.83 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.28 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -81.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $18.29 – $39.89 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.6B · P/B 15.22 · P/S 3.63.
Company News
JP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $80Benzinga · Aug 25, 2026, 12:53 PM
Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $74Benzinga · Aug 21, 2026, 12:48 PM
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $83Benzinga · Aug 20, 2026, 7:46 PM
Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $58Benzinga · Aug 20, 2026, 6:45 PM
Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $46Benzinga · Aug 20, 2026, 3:07 PM
Ultragenyx Nabs FDA Nod for First Gene TherapyBenzinga · Aug 20, 2026, 12:33 PM
Okta To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For ThursdayBenzinga · Aug 20, 2026, 12:19 PM
Ultragenyx Pharmaceutical shares are trading higher after the company announced that the FDA granted accelerated approval for GENGLYCOS. Also, Cantor Fitzgerald maintained an Overweight rating on the stock and raised its price target from $96 to $103.Benzinga · Aug 20, 2026, 11:43 AM
Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving PremarketBenzinga · Aug 20, 2026, 11:25 AM
Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $103Benzinga · Aug 20, 2026, 11:25 AM